Inflammatory Bowel Disease Cell Models for Research

Inflammatory Bowel Disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), affects over 6.8 million people globally (GBD 2017, WHO). Incidence is rising in newly industrialized countries. IBD is a chronic, relapsing inflammatory condition of the gastrointestinal tract, with significant morbidity and reduced quality of life. While not typically fatal, IBD increases risk of colorectal cancer, with a 5-year survival of ~60% for CRC associated with IBD (NCI). Risk factors include genetic predisposition (NOD2, ATG16L1), gut microbiota dysbiosis, and environmental triggers such as diet and smoking.

IBD is ideal for mechanistic studies due to its well-characterized genetic architecture, availability of large GWAS datasets, and the central role of the intestinal epithelium and immune system. Key open questions include the precise molecular pathways linking genetic variants to inflammation, the role of the microbiome, and the mechanisms of fibrosis and cancer progression. Gene-edited cell models allow functional validation of IBD risk loci and drug target identification.

IBD-associated colorectal cancer (CRC) follows a chronic inflammation-dysplasia-carcinoma sequence. Key pathways include:

• • NF-κB signaling: activated by TNF-α and IL-1β, promotes cell survival and inflammation.
• • JAK-STAT pathway: mediates cytokine signaling (IL-6, IL-23), driving T-cell differentiation and inflammation.
• • Wnt/β-catenin pathway: frequently activated in IBD-associated CRC, leading to uncontrolled proliferation.
• • MAPK pathway: involved in stress responses and proliferation, often dysregulated in IBD.
• • PI3K/AKT pathway: promotes cell survival and is commonly upregulated in IBD-related tumors.

Data from TCGA, COSMIC, and ClinVar.

Key signaling networks in IBD:

• • NF-κB pathway: central to inflammation. Key nodes: NOD2, RIPK2, IKK complex, NF-κB1/2.
• • Autophagy pathway: ATG16L1, IRGM, ULK1. Defects lead to impaired bacterial clearance.
• • IL-23/Th17 axis: IL23R, JAK2, STAT3, RORγt. Drives chronic inflammation.
• • TNF-α signaling: TNFSF15, TNFRSF1A, TRAF2. Activates NF-κB and MAPK.
• • Epithelial barrier integrity: MUC2, TJP1, OCLN. Disruption leads to increased permeability.

Organoids are particularly valuable for studying epithelial-immune crosstalk and drug responses.

Animal models for IBD include:

• • Chemically induced models: DSS-induced colitis, TNBS-induced colitis. These are acute models of epithelial damage and inflammation.
• • Genetically engineered mouse models (GEMMs): IL-10 knockout, NOD2 knockout, ATG16L1 mutant mice. These model specific genetic contributions.
• • Adoptive transfer models: Transfer of naïve T cells into immunodeficient mice induces colitis.
• • Patient-derived xenografts (PDX): Used for cancer research, but less common for IBD due to chronic nature.
• • Humanized mice: Engrafted with human immune cells to study human-specific interactions.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as:

• • NOD2 knockout lines: To study loss of bacterial sensing and NF-κB activation.
• • ATG16L1 T300A knock-in lines: To model the common risk variant and assess autophagy function.
• • IL23R knockout lines: To investigate IL-23 signaling and Th17 differentiation.
• • TNF-α reporter lines: To monitor inflammatory responses in real-time.

These models are commercially available as sequence-verified, clonally derived lines, ensuring reproducibility and accelerating research. They are essential for functional validation of GWAS hits and drug target assessment.

Gene-edited cell lines are used to validate the functional impact of IBD-associated genetic variants. For example:

• • NOD2 knockout in Caco-2 cells leads to increased NF-κB activation upon bacterial stimulation, confirming its role in innate immunity.
• • ATG16L1 T300A knock-in in HT-29 cells impairs autophagy and increases IL-1β secretion, linking the variant to inflammation.
• • IL23R knockout in T cells reduces Th17 differentiation, validating its role in the IL-23/Th17 axis.

Isogenic pairs (wild-type vs. knockout/knock-in) are powerful tools for drug screening:

• • Screen for compounds that inhibit NF-κB in NOD2 knockout vs. wild-type cells to identify targeted therapies.
• • Test JAK inhibitors in IL23R knockout vs. wild-type cells to assess specificity.
• • Model resistance to anti-TNF therapy by generating TNFRSF1A knockout lines and screening for alternative pathways.

CRISPR-based synthetic lethality screens can identify novel therapeutic targets and biomarkers:

• • In ATG16L1 mutant cells, screen for genes whose knockdown is selectively lethal, revealing dependencies.
• • Use reporter lines to identify compounds that modulate TNF-α production, serving as potential biomarkers for drug response.